Company: SMNR
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001213900-25-044889
Chunk: 85

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 2
Chunk 85
---
11.1(a) of the Longevity Merger Agreement, the parties entered into a termination agreement (the “Termination Agreement”)
pursuant to which the Longevity Merger Agreement was terminated effective as of the date of the Termination Agreement. 

As a result of the Termination
Agreement, the Longevity Merger Agreement will be of no further force and effect (other than certain customary limited provisions that
survive the termination pursuant to the terms of the Longevity Merger Agreement) and ancillary agreements entered into in connection with
the Longevity Merger Agreement will also automatically terminate in accordance with their respective terms. As a result of the termination
of the Longevity Merger Agreement, Holdco filed the Registration Withdrawal Request on Form RW on August 9, 2024, to withdraw its registration
statement on Form S-4, as amended, initially filed with the SEC on March 29, 2023.   

On July 2, 2024, the Company
issued a press release to announce that it entered into a letter of intent with Semnur Pharmaceuticals, Inc. (“Semnur”), a
wholly owned subsidiary of Scilex Holding Company (“Scilex”), for a potential business combination.

28

On July 10, 2024, the shareholders
of the Company held an extraordinary general meeting of shareholders (the “Shareholder Meeting”) to consider and vote upon
a proposal to amend, by way of special resolution, the Articles to extend the date by which the Company must: (i) consummate a merger,
share exchange, asset acquisition, share purchase, reorganization or similar business combination involving the Company and one or more
businesses or entities (an “initial business combination”); (ii) cease its operations, except for the purpose of winding up,
if it fails to complete such initial business combination; and (iii) redeem 100% of the Company’s Class A ordinary shares, par value
$0.0001 per share (the “Class A ordinary shares”), included as part of the units sold in the Company’s IPO that was
consummated on April 11, 2022, from July 11, 2024 to April 11, 2025, by electing to extend the date to consummate an initial business
combination on a monthly basis for up to nine (9) times by an additional one month each time, unless the closing of the Company’s